Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages 1025-1039

  Chen, Alice P ^a   Setser, Ann ^a   Anadkat, Milan J ^b   Cotliar, Jonathan ^c   Olsen, Elise A ^d   Garden, Benjamin C ^e   Lacouture, Mario E ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adverse events; Cancer treatment; Common terminology criteria for adverse events; Drug reactions; Grading system; Side effects

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACNE; ARTICLE; BOOK; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DAILY LIFE ACTIVITY; DRUG ANTAGONISM; HAIR DISEASE; HUMAN; NEOPLASM; NEWBORN EXFOLIATIVE DERMATITIS; NOMENCLATURE; PARONYCHIA; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ACNEIFORM ERUPTIONS; ACTIVITIES OF DAILY LIVING; ANTINEOPLASTIC AGENTS; DERMATITIS, EXFOLIATIVE; DICTIONARIES AS TOPIC; EPIDERMAL NECROLYSIS, TOXIC; HAIR DISEASES; HUMANS; NEOPLASMS; PARONYCHIA; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN DISEASES; STEVENS-JOHNSON SYNDROME; TERMINOLOGY AS TOPIC;

EID: 84872679025     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.02.010     Document Type: Review

References (35)

1. Agha R, Kinahan K, Bennett CL, Lacouture ME. Dermatologic challenges in cancer patients and survivors. Oncology 2007;21: 1462-72
2. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010;102:47-53
3. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116:3916-23
4. Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 2011;65:624-35
5. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 2008;7:48-54
6. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81
7. NCI. CTCAE. Available from: URL:http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed May, 17, 2010
8. ICH harmonized tripartite guideline post-approval safety data management: Definitions and standards for expedited reporting E2D, current step 4 version. International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. November 12, 2003
9. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010;18:509-22
10. Koo LC, Davis ST, Suttle AB, Friedman CJ, Bartlett-Pandite LN. Incidence of chemotherapy-induced alopecia by chemotherapy regimen: A review of published randomized trials [abstract]. Proc Am Soc Clin Oncol 2002:21 (abstr 2876)
11. Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res 2006;23:2505-14
12. Chalid A, Wolfram S. Chapter 146, Cutaneous lymphoma. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffell DJ, editors. Fitzpatrick's dermatology in general medicine. 7th ed. New York: McGraw-Hill Medical, 2008
13. Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park) 2007;21(Suppl):4-9
14. Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 2009;15:143-55
15. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, et al. Taxane-induced nail changes: Incidence, clinical presentation and outcome. Ann Oncol 2003;14:333-7
16. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500
17. Janusch M, Fischer M, Marsch W, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndromeea frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16:494-9
18. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur J Cancer 2008;44:781-90
19. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19: 1955-61
20. Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash: Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 2008;9:267-74
21. Tomková H, Kohoutek M, Zábojníková M, Pospísková M, Ostrízková L, Gharibyar M. Cetuximab-induced cutaneous toxicity. J Eur Acad Dermatol Venereol 2010;24:692-6
22. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: Pathogenesis, clinical significance, and management. Clin Lung Cancer 2009;10:106-11
23. Mydin AR, Armstrong JG. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol 2007;85:171
24. Fleta-Asín B, Vañó-Galván S, Ledo-Rodríguez A, Truchuelo-Díez M, Jaén-Olasolo P. Facial acneiform rash associated with sorafenib. Dermatol Online J 2009;15:7
25. Buckner JC, Forouzesh B, Erlichman C, Hidalgo M, Boni JP, Dukart G, et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs 2010;28:334-42
26. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
27. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7
28. Pavithran K, Thomas M. Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol 2005;71:288-9
29. Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009;114:485-93
30. Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 1994;331:1272-85
31. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19:142-9
32. Harper JL, Franklin LE, Jenrette JM, Aguero EG. Skin toxicity during breast irradiation: Pathophysiology and management. South Med J 2004;97:989-93
33. Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006;7:45-63
34. Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, Kovacsovics T, et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 2005;211:363-5
35. Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: Results of a survey among German oncologists. Onkologie 2010;33:94-8.